文献速递心血管技术与安全PETCT

68Ga-FAPI PET/CT在轻链型心脏淀粉样变性中的可行性研究

Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2022-09-14

该前瞻性研究纳入30例活检证实的AL淀粉样变性患者(27例合并心脏受累),行68Ga-FAPI-04 PET/CT评估心肌成纤维细胞激活。80%患者左心室摄取增高,分为斑片型和弥漫型;摄取与Mayo分期、NT-proBNP、室间隔厚度、LVEF、细胞外容积及整体应变相关。提示该技术可行,可提供心脏分子表征和疾病分期信息。

要点

  • 68Ga-FAPI-04 PET/CT可显示AL心脏淀粉样变性患者心肌成纤维细胞激活,80%左心室摄取增高。
  • 摄取模式分为斑片型和弥漫型,弥漫型标准化摄取比值和左心室分子容积更高。
  • 心肌摄取与 Mayo 分期、NT-proBNP、室间隔厚度、LVEF、细胞外容积和整体应变相关。

关键影像表现/征象

  • 80%(24/30)患者左心室摄取增高,其中斑片型4例、弥漫型20例,6例未见可见心肌摄取。
  • 弥漫型组标准化摄取比值和左心室分子容积显著高于斑片型组(2.79 mL±1.22 mL vs 1.53 mL±0.66 mL,P=0.045;198.3 mL±59.97 mL vs 127.8 mL±25.82,P=0.005)。
  • 68Ga-FAPI-04摄取与Mayo分期、NT-proBNP、室间隔厚度、LVEF、左心室收缩末期容积、细胞外容积和左心室整体应变显著相关(P<0.05)。

诊断标准与关键数值

  • 根据左心室摄取模式分为斑片型(PET-patchy)、弥漫型(PET-extensive)和阴性(PET-negative)。
  • 弥漫型组标准化摄取比值和左心室分子容积显著高于斑片型组(P=0.045和P=0.005)。

临床应用与阅片要点

  • 阅片时可关注左心室心肌68Ga-FAPI-04摄取是否增高及分布模式(斑片型或弥漫型)。
  • 弥漫型摄取提示更明显的心肌重构,可结合Mayo分期、NT-proBNP、室间隔厚度、LVEF、细胞外容积和整体应变综合评估。
  • 注意部分患者(6/30)可无明显心肌摄取,阴性结果不能排除心脏受累。

局限性

  • 样本量较小(30例),且为单中心前瞻性研究。
  • 仅27例合并AL CA,3例无AL CA,组间比较受限。
  • 心脏磁共振仅18例完成,部分影像相关性分析样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Systemic amyloid light chain (AL) amyloidosis is the most common type of amyloidosis, leading to cardiomyocyte necrosis and interstitial fibrosis. Gallium-68-labeled fibroblast activation protein inhibitor 04 (68Ga-FAPI-04) has recently been introduced for imaging fibroblast activation in cardiac diseases. To date, cardiac fibroblast and cardiac amyloidosis (CA) phenotype activities have not been mapped.

OBJECTIVES: The aim of this study was to evaluate the feasibility of 68Ga-FAPI-04 positron emission tomography (PET)/computed tomography (CT) in assessing AL CA.

METHODS: Thirty consecutive patients (mean age: 59.1 ± 7.7 years; 20 men, 10 women) with biopsy-proven AL amyloidosis were enrolled prospectively (including 27 with AL CA and 3 without AL CA). All patients underwent 68Ga-FAPI-04 PET/CT (107.4 ± 26.5 MBq). Global standardized uptake values and left ventricular (LV) molecular volume were calculated in correlation to echocardiography (n = 30), cardiac magnetic resonance (n = 18), and clinical biomarkers. Subsequently, the patients were categorized as having patchy (PET-patchy), extensive (PET-extensive), and negative (PET-negative) patterns.

RESULTS: Of all patients, 80% (24 of 30) showed increased LV uptake (PET-patchy [n = 4] vs PET-extensive [n = 20]), whereas 6 patients did not show visible myocardial uptake. Standardized uptake value ratio and LV molecular volume were significantly higher in the PET-extensive than the PET-patchy group (2.79 mL ± 1.22 mL vs 1.53 mL ± 0.66 mL [P = 0.045] and 198.3 mL ± 59.97 mL vs 127.8 mL ± 25.82 [P = 0.005], respectively). Additionally, 68Ga-FAPI-04 uptake was significantly correlated with clinical biomarkers (Mayo stage and N-terminal pro-brain natriuretic peptide), interventricular septal thickness, left ventricular ejection fraction (LVEF), LV end-systolic volume, extracellular volume, and LV global strain (P < 0.05).

CONCLUSIONS: 68Ga-FAPI-04 PET/CT is feasible in detecting myocardial fibroblast activation in patients with AL CA in correlation with myocardial remodeling. It might provide complementary information on cardiac molecular characterization and staging of disease.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Wang, Guo, Gao, et al. Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022. PMID: 36357138. doi:10.1016/j.jcmg.2022.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。